OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
OmniComm Systems, Inc. continues to expand its role in the rare disease treatment area with a new agreement. An international biopharmaceutical company has signed a five-year contract to use OmniComm’s suite of eClinical solutions to build and manage global Phase III and Phase IV studies targeting rare pediatric diseases.
For more information, click here.